证券代码：002001 证券简称：新和成 公告编号：2024-028 浙江新和成股份有限公司 第九届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 浙江新和成股份有限公司董事会 2024 年 7 月 18 日 为加快和完善公司新材料板块业务布局，董事会同意浙江新和成股份有限公 司与天津经济技术开发区管理委员会签署《投资合作协议》，投资建设尼龙新材 料项目，总投资约人民币 100 亿元（以实际投资为准）。 全文详见公司同日在指定信息披露媒体及巨潮资讯网 （http://www.cninfo.com.cn）刊登的公告。 二、会议以 11 票同意，0 票反对，0 票弃权审议通过《关于召开公司 2024 年第一次临时股东大会的议案》。 董事会同意 2024 年 8 月 2 日下午 14:30 在公司会议室召开 2024 年第一次临 时股东大会，本次股东大会将采用现场表决和网络投票相结合的方式进行。 全文详见公司同日在指定信息披露媒体及巨潮资讯网 （http://www.cninfo.com.cn）刊登的公告。 浙江新和成股份有限公 ...

关于对外投资并签署《投资合作协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002001 证券简称：新和成 公告编号：2024-029 浙江新和成股份有限公司 上述项目主体完成工商登记后，企业名称有变更的，需另行签署补充协议对 项目主体进行确认；企业名称一致的，由项目主体出具确认函对协议内容予以确 认。甲乙双方同意，本协议项下约定的应当由项目主体享有的权利和承担的义务 由成立后的项目主体享有并承担，乙方对本协议项下应当由项目主体承担的责任 或义务不承担任何连带或者非连带的责任。 一、对外投资概述 浙江新和成股份有限公司（以下简称"公司"）于2024年7月17日召开的第 九届董事会第六次会议审议通过《关于对外投资并签署<投资合作协议>的议案》， 同意公司与天津经济技术开发区管理委员会签署《投资合作协议》，在天津南港 工业区投资建设尼龙新材料项目，总投资约人民币100亿元（以实际投资为准）。 本次对外投资事项尚需提交公司股东大会审议，根据《深圳证券交易所股票 上市规则》，本次对外投资事项不构成关联交易，亦不构成《上市公司重大资产 重组管理办 ...

医药生物/化学制药 新和成(002001.SZ) 2024 年 07 月 16 日 投资评级:买入(维持) ——公司信息更新报告 | --- | --- | |-------------------------|-------------------------| | 金益腾(分析师) | 徐正凤(分析师) | | jinyiteng@kysec.cn | xuzhengfeng@kysec.cn | | 证书编号:S0790520020002 | 证书编号:S0790524070005 | | --- | --- | |--------------------|-------------| | 日期 | 2024/7/15 | | 当前股价(元) | 20.48 | | 一年最高最低(元) | 20.70/15.30 | | 总市值(亿元) | 633.02 | | 流通市值(亿元) | 625.56 | | 总股本(亿股) | 30.91 | | 流通股本(亿股) | 30.54 | | 近 3 个月换手率(%) | 45.55 | 股价走势图 | --- | --- | |---------|----- ...

公 司 报 告│ 公 司 点 评 研 究 事件: 新和成(002001) 营养品景气共振,业绩超预期 7 月 11 日晚,公司披露业绩预告,预计 2024 年上半年实现归母净利润 20.77~22.25 亿元,同比增长 40%~50%;扣非净利润预计 20.63~22 亿元, 同比增长 50%~60%;基本每股收益 0.67~0.72 元/股。 营养品主业景气向上,业绩超市场预期 单季度看,2024Q2 公司实现归母净利润为 12.07~13.55 亿元(均值 12.81 亿元),环比+39%~56%(均值+47%),同比+44%~61%(均值+53%)。业绩同环 比大幅提升主要系公司营养品业务板块主要产品的销售数量、价格较上年 同期增长。 上半年公司实现维生素与蛋氨酸主业的景气共振。分产品看,VE、VA 行业 寡头集中,需求改善契机下,头部企业集中挺价,年初以来 VE、VA 价格分 别上涨了 21%、43%至 85、88 元/公斤;蛋氨酸全球 CR4 已来到 73%,定价 逻辑逐步转向寡头定价,Q2 淡季价格依然坚挺,单季度均价为 21.6 元/公 斤,比去年同期增长了 30%。 展望后市,维生素行业检修较 ...

Investment Rating - The report maintains an "Outperform" rating for the company [5]. Core Views - The company has announced a strong performance forecast for the first half of 2024, expecting a net profit attributable to shareholders of between 2.08 billion yuan (YoY +40%) and 2.22 billion yuan (YoY +50%), with a non-recurring net profit of between 2.06 billion yuan (YoY +50%) and 2.20 billion yuan (YoY +60%) [5]. - The vitamin segment is expected to continue its recovery, with the average market prices for key products such as VA, VE, and VC showing increases of 6.17%, 7.87%, and 7.7% respectively in Q2 2024 [5]. - The company is advancing its new materials projects, including a significant investment in a joint venture with Sinopec for a liquid methionine project, which aims to enhance its competitive position in the global market [5]. Financial Summary - The company reported total revenue of 15.12 billion yuan in 2023, with a projected increase to 19.34 billion yuan in 2024, representing a YoY growth rate of 27.9% [7]. - The net profit attributable to shareholders is expected to rise from 2.70 billion yuan in 2023 to 4.55 billion yuan in 2024, reflecting a YoY growth rate of 68.1% [7]. - The earnings per share (EPS) is projected to increase from 0.87 yuan in 2023 to 1.47 yuan in 2024 [8].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of RMB 22.61 [5][7]. Core Views - The company is expected to achieve a net profit attributable to shareholders of RMB 20.8-22.2 billion for the first half of 2024, representing a year-on-year growth of 40%-50% [1]. - The main products in the nutrition segment have seen an increase in both sales volume and price, contributing to the overall performance growth in 2024 [2]. - The recovery trend in the pricing of key products such as Vitamin A and E is expected to continue, supported by export demand and improved supply dynamics [3]. Summary by Sections Financial Performance - For 2024, the company forecasts a net profit of RMB 41 billion, RMB 46 billion, and RMB 52 billion for the years 2024, 2025, and 2026 respectively, with corresponding EPS of RMB 1.33, RMB 1.50, and RMB 1.68 [1][4]. - The revenue for 2024 is projected to be RMB 17.75 billion, with a growth rate of 17.44% compared to 2023 [4]. Product Pricing and Market Trends - The average market prices for Vitamin A, Vitamin E, and methionine in Q2 2024 are expected to be RMB 8.6, RMB 7.1, and RMB 2.2 million per ton, showing a quarter-on-quarter increase of 5%, 8%, and a slight decrease of 1% respectively [2]. - The prices of Vitamin A and E are showing signs of recovery, while methionine prices have also increased year-on-year [2][3]. Future Growth Prospects - The company is advancing several new projects, including a 250,000-ton/year methionine project and a joint venture with Sinopec for an 18,000-ton/year liquid methionine project, which are expected to support future growth [3]. - The successful production of new projects in the flavor and fragrance segment and the new materials segment is anticipated to contribute to high-quality growth in the coming years [3].

Financial Performance Forecast - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 207.652 million and 222.484 million CNY, representing a year-on-year increase of 40% to 50% from 148.323 million CNY [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 206.283 million and 220.035 million CNY, reflecting a year-on-year growth of 50% to 60% from 137.522 million CNY [3]. - The basic earnings per share are projected to be between 0.67 CNY and 0.72 CNY, compared to 0.48 CNY per share in the same period last year [3]. Performance Drivers - The growth in performance is attributed to an increase in both sales volume and prices of the main products in the nutrition business segment compared to the same period last year [4]. Financial Reporting and Risks - The financial data in this earnings forecast has not been audited by a registered accounting firm [4]. - The performance forecast is based on preliminary calculations by the company's finance department, and specific financial data will be disclosed in the 2024 semi-annual report [5]. - Investors are advised to pay attention to investment risks associated with this earnings forecast [5].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for its stock performance [4][7]. Core Views - The vitamin industry has been at a low point for the past two years, but there are signs of recovery as downstream farming profits improve and exports increase. The company, as a leading global vitamin producer, is expected to benefit from this recovery [4][5]. - Recent price increases for various vitamins, including a rise in the average price of VA to 83 RMB/kg and VE to 74 RMB/kg, suggest a strengthening market. The overall vitamin supply-demand dynamics are anticipated to improve [5][6]. - The company is positioned as a leader in the vitamin market, with significant production capacities for VA and VE, and is also expanding into methionine production, which is expected to contribute to profit growth [6][7]. Summary by Sections Company Information - The company operates in the pharmaceutical and biotechnology sector, with a current stock price of 19.16 RMB and a market capitalization of 58.524 billion RMB. The stock has seen a 29.7% increase over the past year [1][2]. Recent Ratings - The company has received "Trading Buy" ratings in previous reports, with the latest rating issued on August 30, 2023, at a closing price of 15.99 RMB [2]. Product Portfolio - The company's product mix includes 65.3% nutrition products, 21.7% flavor and fragrance products, 7.9% new materials, and 5.1% other categories [2]. Price Trends and Market Dynamics - Vitamin prices have shown signs of recovery, with significant increases noted in June 2024. The report highlights that the demand for vitamins, particularly as feed additives, is expected to rise due to improved farming profits [5][6]. Financial Projections - The company is projected to achieve net profits of 36 billion RMB in 2024, 45 billion RMB in 2025, and 55 billion RMB in 2026, reflecting year-on-year growth rates of 33%, 24%, and 23% respectively. The estimated earnings per share (EPS) for these years are 1.17 RMB, 1.44 RMB, and 1.77 RMB [7][8].

本资产评估报告依据中国资产评估准则编制 浙江新和成股份有限公司拟进行股权转 让涉及的琼海博鳌丽都置业有限公司 股东全部权益价值评估项目 资 产 评 估 报 告 坤元评报〔2024〕491 号 （共一册 第一册） 坤元资产评估有限公司 2024 年 6 月 13 日 | 报告编码: | 3333020001202400545 | | --- | --- | | 合同编号: | H-HZ24-000635 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 坤元评报(2024) 491号 | | 报告名称: | 浙江新和成股份有限公司拟进行股权转让涉及的琼 海博鳌丽都置业有限公司股东全部权益价值评估项 | | | 目资产评估报告 | | 评估结论: | 82,791,016.25元 | | 评估报告日: | 2024年06月13日 | | 评估机构名称: | 坤元资产评估有限公司 | | 签名人员: | 周敏 (资产评估师) 会员编号:33050007 | | | 袁满意 (资产评估师) 会员编号:33100006 | | | Comments of the Comments of Chil ...

为进一步优化公司资产，完善产业结构，聚焦精细化工主业，提高盈利水平 和资产质量。公司将全资子公司琼海博鳌丽都置业有限公司（以下简称"丽都置 业"）100%股权以人民币 8,279.10 万元的价格出售给新和成控股集团有限公司 （以下简称"新和成控股公司"）。 证券代码：002001 证券简称：新和成 公告编号：2024-026 浙江新和成股份有限公司 关于出售资产暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 浙江新和成股份有限公司（以下简称"公司"或"本公司"）于2024年6月 18日召开第九届董事会第五次会议，以5票同意，0票反对，0票弃权审议通过了 《关于出售资产暨关联交易的议案》，关联董事胡柏藩、胡柏剡、石观群、王学 闻、王正江、周贵阳进行了回避表决。本事项在提交董事会审议前已经独立董事 专门会议审议通过。 丽都置业为公司全资子公司，经坤元资产评估有限公司评估，截至 2024 年 4 月 30 日，采用资产基础法对丽都置业的全部股东权益评估值为 82,791,016.25 元，本次交易价格为评估价值，即 8,279.10 ...